Evidence map›Paper›PMID 34969967›Full record

ArticleScientific reports2021

Humoral immune response to SARS-CoV-2 in five different groups of individuals at different environmental and professional risk of infection.

Silvia Novello, Massimo Terzolo, Berchialla Paola, Martina Gianetta, Valentina Bianco, Francesca Arizio, Dalila Brero, Anna Maria Elena Perini, Adriana Boccuzzi, Valeria Caramello and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Silvia Novello *Department of Oncology at San Luigi Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.
Massimo Terzolo *Department of Clinical & Biological Sciences at San Luigi Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.
Berchialla PaolaDepartment of Clinical & Biological Sciences at San Luigi Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.ORCID 0000-0001-5835-5638
Martina GianettaDepartment of Oncology at San Luigi Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.
Valentina BiancoDepartment of Oncology at San Luigi Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.
Francesca ArizioDepartment of Oncology at San Luigi Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.
Dalila BreroDepartment of Clinical & Biological Sciences at San Luigi Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.
Anna Maria Elena PeriniDepartment of Clinical & Biological Sciences at San Luigi Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.
Adriana BoccuzziEmergency Care Division, San Luigi Hospital, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.
Valeria CaramelloEmergency Care Division, San Luigi Hospital, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.
Alberto PerboniRespiratory Medicine Division, San Luigi Hospital, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.
Fabio BellaviaRespiratory Medicine Division, San Luigi Hospital, Regione Gonzole 10, 10043, Orbassano, Torino, Italy.
Giorgio Vittorio Scagliotti *Department of Oncology at San Luigi Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Torino, Italy. giorgio.scagliotti@unito.it.
University of Turin · ITOspedale San Luigi Gonzaga · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is partially unknown whether the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection persists with time. To address this issue, we detected the presence of SARS-CoV-2 antibodies in different groups of individuals previously diagnosed with COVID-19 disease (group 1 and 2), or potentially exposed to SARS-CoV-2 infection (group 3 and 4), and in a representative group of individuals with limited environmental exposure to the virus due to lockdown restrictions (group 5). The primary outcome was specific anti-SARS-CoV-2 antibodies in the different groups assessed by qualitative and quantitative analysis at baseline, 3 and 6 months follow-up. The seroconversion rate at baseline test was 95% in group 1, 61% in group 2, 40% in group 3, 17% in group 4 and 3% in group 5. Multivariate logistic regression analysis revealed male gender, close COVID-19 contact and presence of COVID-19 related symptoms strongly associated with serological positivity. The percentage of positive individuals as assessed by the qualitative and quantitative tests was superimposable. At the quantitative test, the median level of SARS-CoV-2 antibody levels measured in positive cases retested at 6-months increased significantly from baseline. The study indicates that assessing antibody response to SARS-CoV-2 through qualitative and quantitative testing is a reliable disease surveillance tool.

Indexed as

COVID-19PandemicsAntibodies, ViralDiagnostic Tests, RoutineFemaleHumansMaleMiddle AgedOccupational ExposureRisk FactorsAntibodies, Viral

Identifiers

PMID34969967
PMCPMC8718534
OpenAlexW4200288788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.